Scarica l'app Stockscreener
497.27
0.24%
-1.21
Dopo l'orario di chiusura:
497.27
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché UTHR Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$498.48
Aprire:
$501.49
Volume 24 ore:
1.18M
Relative Volume:
2.41
Capitalizzazione di mercato:
$21.33B
Reddito:
$3.17B
Utile/perdita netta:
$1.29B
Rapporto P/E:
18.35
EPS:
27.0947
Flusso di cassa netto:
$1.01B
1 W Prestazione:
-1.31%
1M Prestazione:
-2.20%
6M Prestazione:
-7.92%
1 anno Prestazione:
+23.18%
Intervallo 1D:
$492.59
$503.32
Intervallo di 1 settimana:
$492.59
$509.06
Portata 52W:
$402.50
$609.35
United Therapeutics Corp Stock (UTHR) Company Profile
Nome
United Therapeutics Corp
Settore
Telefono
(301) 608-9292
Indirizzo
1000 SPRING ST, SILVER SPRING, MD
Compare UTHR vs TAK, TEVA, HLN, ZTS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UTHR
United Therapeutics Corp
|
497.27 | 21.32B | 3.17B | 1.29B | 1.01B | 27.09 |
TAK
Takeda Pharmaceutical Co Adr
|
19.05 | 58.31B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
39.19 | 43.22B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.36 | 40.41B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
73.02 | 30.15B | 9.51B | 2.64B | 2.14B | 6.0361 |
United Therapeutics Corp Stock (UTHR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-10 | Iniziato | Raymond James | Outperform |
| 2025-10-20 | Iniziato | Wells Fargo | Underweight |
| 2025-09-26 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-06-02 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2025-04-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2024-07-11 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-02-12 | Aggiornamento | Goldman | Sell → Neutral |
| 2024-02-05 | Iniziato | Leerink Partners | Outperform |
| 2023-12-08 | Iniziato | Wells Fargo | Overweight |
| 2022-12-06 | Iniziato | UBS | Buy |
| 2022-12-05 | Iniziato | Goldman | Sell |
| 2022-10-11 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-20 | Reiterato | BofA Securities | Underperform |
| 2022-09-19 | Ripresa | Wedbush | Outperform |
| 2022-02-11 | Iniziato | BTIG Research | Neutral |
| 2021-07-14 | Aggiornamento | Argus | Hold → Buy |
| 2021-04-26 | Ripresa | Credit Suisse | Outperform |
| 2021-02-01 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2020-09-14 | Ripresa | JP Morgan | Overweight |
| 2020-06-25 | Reiterato | H.C. Wainwright | Neutral |
| 2020-03-10 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-02-27 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-01-31 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2019-12-03 | Iniziato | BofA/Merrill | Underperform |
| 2019-08-01 | Aggiornamento | Jefferies | Underperform → Hold |
| 2019-08-01 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2019-07-01 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2019-05-17 | Aggiornamento | UBS | Sell → Neutral |
| 2019-05-09 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-12 | Aggiornamento | Standpoint Research | Hold → Buy |
| 2018-08-08 | Downgrade | Credit Suisse | Neutral → Underperform |
| 2018-04-03 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-02-22 | Reiterato | Barclays | Underweight |
| 2018-01-18 | Ripresa | Credit Suisse | Underperform |
| 2017-12-27 | Reiterato | Wedbush | Outperform |
| 2017-04-27 | Reiterato | Wedbush | Outperform |
| 2017-03-30 | Iniziato | UBS | Sell |
| 2017-03-16 | Iniziato | Credit Suisse | Underperform |
Mostra tutto
United Therapeutics Corp Borsa (UTHR) Ultime notizie
United Therapeutics (UTHR) CEO exercises options, sells 9,500 shares - Stock Titan
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now? - Zacks Investment Research
United Therapeutics (UTHR) Sets $477.6 Million Buyback. Can Pipeline Funding Keep Pace? - Yahoo Finance
United Therapeutics (UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan
United Therapeutics CEO Martine Rothblatt sells $4.7m in stock By Investing.com - Investing.com Australia
United Therapeutics at Cantor healthcare conference: fibrosis push widens By Investing.com - Investing.com Australia
United Therapeutics CEO Martine Rothblatt sells $4.7m in stock - investing.com
United Therapeutics (UTHR) CEO exercises options and sells 9,500 shares in preset plan - Stock Titan
United Therapeutics Launches $477.6M Accelerated Share Buyback - Minichart
United Therapeutics Launches $477.6 Million Accelerated Share Repurchase With Citi - TradingView
United Therapeutics (UTHR) moves to return $4B to shareholders with new buyback - Stock Titan
United Therapeutics (UTHR) CEO sells 9,500 shares under preset trading plan - Stock Titan
United Therapeutics Corporation at Wells Fargo Healthcare Conference Transcript - GuruFocus
United Therapeutics Corporation Announces Accelerated Share Repurchase Agreement for Remainder of $2.0 Billion Authorization - marketscreener.com
United Therapeutics Corporation (UTHR) Stock Analysis: Insights on a 36.24% Potential Upside - DirectorsTalk Interviews
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares under 10b5-1 plan - Stock Titan
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
United Therapeutics (UTHR) Down 8% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Anheuser-Busch plant in Merrimack sold to United Therapeutics for $47.5M - UnionLeader.com
United Therapeutics EVP Paul A. Mahon Executes Stock Option Exercise and Sells Shares Under 10b5-1 Plan - kalkinemedia.com
United Therapeutics (UTHR) counsel sells 8,300 shares under preset plan - Stock Titan
United Therapeutics (UTHR) CEO offloads 9,500 shares in planned trade - Stock Titan
United Therapeutics (NASDAQ:UTHR) Offers Growth At A Fair Price - Kalkine Media
United Therapeutics (NASDAQ:UTHR) Fits the Growth-at-a-Reasonable-Price Model - ChartMill
Merrimack’s Anheuser-Busch property sold for $47m - The Cabinet Press
United Therapeutics Corp (UTHR) Stock Down 4.1% but Still Overva - GuruFocus
United Therapeutics (UTHR) CEO sells 9,500 shares under trading plan - Stock Titan
United Therapeutics Slides as Investors Weigh Insider Selling Against a New Regulatory Milestone - Quiver Quantitative
United Therapeutics FDA Accepts Tyvaso IPF Filing | UTHR Stock News - stocktitan.net
United Therapeutics (UTHR) CEO sells more shares under preset trading plan - Stock Titan
Stewartville's xenotransplant pig facility is ready for animals - Post Bulletin
Four healthcare conferences will host United Therapeutics executives in September. The talks will be streamed live. - Stock Titan
United Therapeutics (UTHR) CEO sells 9,500 shares under preset plan - Stock Titan
United Therapeutics Corporation (UTHR) Stock Analysis: Evaluating a 28.88% Upside Potential in the Healthcare Sector - DirectorsTalk Interviews
United Therapeutics (UTHR) CEO sells shares via preset options plan - Stock Titan
United Therapeutics to present drug trial data at conferences - Investing.com
United Therapeutics will present data showing improved lung function in idiopathic pulmonary fibrosis - Stock Titan
FDA Accepts United Therapeutics' NDA Filing for Ralinepag in PAH - Yahoo Finance
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares in preset plan - Stock Titan
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 under 10b5-1 plan - Stock Titan
United Therapeutics Ralinepag NDA Accepted by FDA With June 2027 Decision Date - Yahoo Finance
United Therapeutics (NASDAQ: UTHR) CEO sale part of 1,734,410-option 10b5-1 plan - Stock Titan
United Therapeutics (UTHR) legal chief sells 8,300 shares - Stock Titan
United Therapeutics (NASDAQ: UTHR) CEO trades under 1,734,410-option 10b5-1 plan - Stock Titan
United Therapeutics (NASDAQ:UTHR) Stands Out as a Quality Stock with Durable Profitability and Strong Returns - ChartMill
ETFs Investing in United Therapeutics Corporation Stocks - TradingView
United Therapeutics (UTHR) CEO sells shares under preset trading plan - Stock Titan
United Therapeutics (NASDAQ: UTHR) CEO sells 9,500 shares - Stock Titan
United Therapeutics (UTHR) Q2 2026 Earnings Call Transcript - AOL.com
United Therapeutics Completes Enrollment in Phase 3 PPF Trial of Tyvaso - marketscreener.com
United Therapeutics completes enrollment in lung fibrosis trial - Investing.com
United Therapeutics Corp Azioni (UTHR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
United Therapeutics Corp Azioni (UTHR) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| ROTHBLATT MARTINE A | Chairperson & CEO |
Sep 15 '26 |
Sale |
501.59 |
9,500 |
4,765,119 |
324,443 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Sep 14 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Sep 14 '26 |
Sale |
504.12 |
9,500 |
4,789,152 |
324,443 |
| Mesa Nilda | Director |
Sep 14 '26 |
Option Exercise |
110.86 |
130 |
14,412 |
6,560 |
| Mesa Nilda | Director |
Sep 14 '26 |
Sale |
505.87 |
228 |
115,338 |
5,580 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Sep 11 '26 |
Option Exercise |
117.76 |
9,500 |
1,118,720 |
333,943 |
| ROTHBLATT MARTINE A | Chairperson & CEO |
Sep 11 '26 |
Sale |
500.82 |
9,500 |
4,757,773 |
324,443 |
0.65%
0.52%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):